CRDF实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	2.14M
平均成交量	1.91M
市值	157.38M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.78
ATR14	$0.0660 (1.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Levine James E.	Buy	205 008	Stock Options
2024-03-07	Kabbinavar Fairooz	Buy	205 008	Stock Options
2024-03-07	Smeal Tod	Buy	205 008	Stock Options
2024-03-07	Erlander Mark	Buy	510 000	Stock Options
2023-12-19	Pace Gary W	Buy	30 000	Common Stock

INSIDER POWER
82.07
Last 96 transactions
Buy: 6 518 913 \| Sell: 700 088

音量相关性

長: -0.47 (neutral)

短: -0.33 (neutral)

Signal:(40.926) Neutral

Cardiff Oncology Inc 相关性

10 最正相关
EBAY	0.964
CPRT	0.963
XLRN	0.96
MSTR	0.96
DAX	0.958
DWAC	0.956
GRMN	0.955
CRAI	0.953
FDT	0.953
BWMX	0.952

10 最负相关
VORB	-0.942
TWKS	-0.938
PEAR	-0.934
SMSI	-0.934
TEDU	-0.923
UONE	-0.919
TTEC	-0.918
QNRX	-0.915
BRQS	-0.915
BMBL	-0.914

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cardiff Oncology Inc 相关性 - 货币/商品

0.26
( neutral )

0.03
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.60
( weak negative )

-0.02
( neutral )

Cardiff Oncology Inc 财务报表

Annual	2023
营收:	$488 000
毛利润:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2023
营收:	$488 000
毛利润:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2022
营收:	$386 000
毛利润:	$186 000 (48.19 %)
EPS:	$-0.860

FY	2021
营收:	$359 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.